GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (XCNQ:METX) » Definitions » Cash-to-Debt

ME Therapeutics Holding (XCNQ:METX) Cash-to-Debt : No Debt (1) (As of Feb. 2024)


View and export this data going back to 2023. Start your Free Trial

What is ME Therapeutics Holding Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. ME Therapeutics Holding's cash to debt ratio for the quarter that ended in Feb. 2024 was No Debt (1).

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, ME Therapeutics Holding could pay off its debt using the cash in hand for the quarter that ended in Feb. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for ME Therapeutics Holding's Cash-to-Debt or its related term are showing as below:

XCNQ:METX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.4   Med: 14.04   Max: No Debt
Current: 33.68

During the past 2 years, ME Therapeutics Holding's highest Cash to Debt Ratio was No Debt. The lowest was 0.40. And the median was 14.04.

XCNQ:METX's Cash-to-Debt is ranked better than
69.64% of 1535 companies
in the Biotechnology industry
Industry Median: 6.49 vs XCNQ:METX: 33.68

ME Therapeutics Holding Cash-to-Debt Historical Data

The historical data trend for ME Therapeutics Holding's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

ME Therapeutics Holding Cash-to-Debt Chart

ME Therapeutics Holding Annual Data
Trend Aug22 Aug23
Cash-to-Debt
0.40 16.18

ME Therapeutics Holding Quarterly Data
Aug22 Dec22 May23 Aug23 Nov23 Feb24
Cash-to-Debt Get a 7-Day Free Trial 12.25 15.83 16.18 9.55 No Debt

Competitive Comparison of ME Therapeutics Holding's Cash-to-Debt

For the Biotechnology subindustry, ME Therapeutics Holding's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ME Therapeutics Holding's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ME Therapeutics Holding's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where ME Therapeutics Holding's Cash-to-Debt falls into.


ME Therapeutics Holding Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

ME Therapeutics Holding's Cash to Debt Ratio for the fiscal year that ended in Aug. 2023 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=0.647 / (0.04 + 0)
=16.18

ME Therapeutics Holding's Cash to Debt Ratio for the quarter that ended in Feb. 2024 is calculated as:

ME Therapeutics Holding had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ME Therapeutics Holding  (XCNQ:METX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

ME Therapeutics Holding Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of ME Therapeutics Holding's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

ME Therapeutics Holding (XCNQ:METX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (XCNQ:METX) » Definitions » Cash-to-Debt
Comparable Companies
Traded in Other Exchanges
Q9T:Germany
Address
177 Robson Street, Vancouver, BC, CAN, V6B 0N3
Website
https://www.metherapeutics.com
ME Therapeutics Holding Inc operates its business through ME Therapeutics. It is a preclinical-stage biotechnology company working on novel cancer-fighting drugs in the field of Immuno-Oncology (IO). It is developing preclinical data for its myeloid-targeted candidate assets using validated cancer models.

ME Therapeutics Holding (XCNQ:METX) Headlines

No Headlines